These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31570485)

  • 1. Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan.
    Yasuoka S; Yuasa T; Ogawa M; Komai Y; Numao N; Yamamoto S; Kondo Y; Yonese J
    Anticancer Res; 2019 Oct; 39(10):5803-5809. PubMed ID: 31570485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
    Terada N; Kamoto T; Tsukino H; Mukai S; Akamatsu S; Inoue T; Ogawa O; Narita S; Habuchi T; Yamashita S; Mitsuzuka K; Arai Y; Kandori S; Kojima T; Nishiyama H; Kawamura Y; Shimizu Y; Terachi T; Sugi M; Kinoshita H; Matsuda T; Yamada Y; Yamamoto S; Hirama H; Sugimoto M; Kakehi Y; Sakurai T; Tsuchiya N
    BMC Cancer; 2019 Feb; 19(1):156. PubMed ID: 30770773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer.
    Kosaka T; Hongo H; Watanabe K; Mizuno R; Kikuchi E; Oya M
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1061-1066. PubMed ID: 30283980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer.
    Fujiwara M; Yuasa T; Yasuoka S; Komai Y; Oguchi T; Fujiwara R; Numao N; Yamamoto S; Yonese J
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):525-531. PubMed ID: 34110449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
    Med Oncol; 2017 Aug; 34(8):141. PubMed ID: 28718092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
    Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
    Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration-resistant prostate cancer: A local experience of a multicenter retrospective study.
    Takai M; Kato S; Nakano M; Fujimoto S; Iinuma K; Ishida T; Taniguchi M; Tamaki M; Uno M; Takahashi Y; Komeda H; Koie T
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):238-244. PubMed ID: 32970933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer.
    Robin G; Basappa NS; North S; Ghosh S; Kolinsky M
    Curr Oncol; 2024 Aug; 31(9):5080-5087. PubMed ID: 39330003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel.
    Miyake H; Matsushita Y; Watanabe H; Tamura K; Suzuki T; Motoyama D; Ito T; Sugiyama T; Otsuka A
    Anticancer Res; 2018 Jul; 38(7):4179-4185. PubMed ID: 29970547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study.
    Suzuki K; Matsubara N; Kazama H; Seto T; Tsukube S; Matsuyama H
    Jpn J Clin Oncol; 2019 Dec; 49(12):1157-1163. PubMed ID: 31361807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between Automated Bone Scan Index Change after Cabazitaxel and Survival among Men with Castration-Resistant Prostate Cancer.
    Miyoshi Y; Sakamoto S; Kawahara T; Uemura K; Yokomizo Y; Uemura H
    Urol Int; 2019; 103(3):279-284. PubMed ID: 31461725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel.
    Kosaka T; Shinojima T; Morita S; Oya M
    Cancer Sci; 2018 May; 109(5):1570-1575. PubMed ID: 29493842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
    Oh WK; Miao R; Vekeman F; Sung J; Cheng WY; Gauthier-Loiselle M; Dhawan R; Duh MS
    Med Oncol; 2017 Aug; 34(9):160. PubMed ID: 28795333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
    Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
    Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer.
    Ito T; Kanao K; Takahara K; Ando R; Yasui T; Shiroki R; Sumitomo M; Miyake H
    Anticancer Res; 2019 Jun; 39(6):3089-3094. PubMed ID: 31177153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study.
    Shiota M; Nakamura M; Yokomizo A; Tomoda T; Sakamoto N; Seki N; Hasegawa S; Yunoki T; Harano M; Kuroiwa K; Eto M
    Med Oncol; 2019 Feb; 36(4):32. PubMed ID: 30815799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
    Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands.
    Westgeest HM; Kuppen MCP; van den Eertwegh AJM; de Wit R; Coenen JLLM; van den Berg HPP; Mehra N; van Oort IM; Fossion LMCL; Hendriks MP; Bloemendal HJ; van de Luijtgaarden ACM; Ten Bokkel Huinink D; van den Bergh ACMF; van den Bosch J; Polee MB; Weijl N; Bergman AM; Uyl-de Groot CA; Gerritsen WR
    Clin Genitourin Cancer; 2019 Oct; 17(5):e946-e956. PubMed ID: 31439536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
    Kosaka T; Hongo H; Oya M
    BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.